Other names: CKD-aP; Uremic Pruritus

Chronic Kidney Disease-associated Pruritus (CKD-aP) is a debilitating systemic itch condition that affects a large number of hemodialysis patients.

CKD-aP is thought to be caused by a combination of factors, including immune system dysfunction, build-up of toxins, metabolic abnormalities, systemic inflammation, and altered endogenous opioid levels.

CKD-aP itching mainly affects the face, chest, and limbs, and may be generalized. It usually presents as large symmetric reddened areas of skin, often at night. The intensity varies from mild discomfort, to complete restlessness day and night.

CKD-aP is associated with poor quality of life, depression, anxiety, sleep disturbance, and increased mortality.

Korsuva (difelikefalin) is the first FDA approved treatment for CKD-aP. It works to alleviate pruritus by selectively targeting peripheral kappa-opioid receptors.

Drugs used to treat Chronic Kidney Disease-Associated Pruritus